Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16/18/52 - PubMed
3 hours ago
- #therapeutic vaccine
- #HPV vaccine
- #adenovirus vector
- KDTV001 is a trivalent HPV therapeutic vaccine targeting HPV16/18/52 using an adenovirus 5 vector.
- Preclinical studies show KDTV001 elicits strong immune responses, cross-reactivity, and tumor regression in mice.
- Single-cell sequencing indicates the vaccine remodels the tumor microenvironment and expands cytotoxic CD8+ T cells.
- Optimization of booster schedules helps overcome pre-existing immunity to the adenovirus vector.
- Relevance to humans is supported by T-cell activation in HLA-transgenic mice and PBMC co-cultures.
- The study received funding from Chinese national and provincial science and technology projects.